Price
No data yet.
Social Signal Score
Analyst Ratings
52 analystsRevenue
$6.52B+106.53%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kevin A. Lobo
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 56,000
- Beta
- 0.78
- Country
- US
- Piotroski score
- 9 / 9 (Strong)
- Altman Z-score
- 4.81
Financials
Revenue
$6.52B+106.5%Net Income
$753.00M+47.6%EBITDA
$1.29B+74.8%Free Cash Flow
$1.22B+142.4%EPS (diluted)
$1.96+46.3%Shares Outstanding (diluted)
384.70M+1.5%Operating Expenses
$2.75BCash & Debt
$3.27BReturn of Capital
$1.34BRevenue by Segment (annual)
$25.12BDividend per Share
$0.88Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $25.12B | $3.25B | $8.49 |
| 2024 | $22.59B | $2.99B | $7.86 |
| 2023 | $20.50B | $3.17B | $8.34 |
| 2022 | $18.45B | $2.36B | $6.23 |
| 2021 | $17.11B | $1.99B | $5.29 |
| 2020 | $14.35B | $1.60B | $4.26 |
| 2019 | $14.88B | $2.08B | $5.57 |
| 2018 | $13.60B | $3.55B | $9.50 |
| 2017 | $12.44B | $1.02B | $2.73 |
| 2016 | $11.32B | $1.65B | $4.40 |
| 2015 | $9.95B | $1.44B | $3.82 |
| 2014 | $9.68B | $515.00M | $1.36 |
| 2013 | $9.02B | $1.01B | $2.66 |
| 2012 | $8.66B | $1.30B | $3.41 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SYK's reported EPS growth of 7.3% a year over 13 years.
- EPS in 5 years
- $12.08
- Implied price
- $495.27
- Return from $313.08
- 9.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $246.24 — -21.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 29 | 35 | 41 | 47 | 53 |
|---|---|---|---|---|---|
| -2.7% | -7.3% | -3.7% | -0.6% | 2.1% | 4.6% |
| 2.3% | -2.5% | 1.2% | 4.5% | 7.4% | 10.0% |
| 7.3% | 2.3% | 6.2% | 9.6% | 12.6% | 15.4% |
| 12.3% | 7.0% | 11.1% | 14.7% | 17.9% | 20.8% |
| 17.3% | 11.8% | 16.1% | 19.8% | 23.1% | 26.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60+20.00%Social Signal Score
Mentions (67)
- Newsmarketbeat.com·3d ago·Positive
Stryker Sticks to Growth Goals Despite Cyberattack and Slower Orthopedic Market Stryker NYSE: SYK expects to maintain its long-term growth and margin goals despite a cyberattack, supply disruptions and a softer U.S. orthopedic market, executives said at the London Healthcare Conference.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Stryker Corporation (SYK) Presents at Jefferies Global Healthcare Conference 2026 Transcript Stryker Corporation (SYK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - News (RSS)investing·11d ago·Neutral
Why did Stryker surge 19% after cutting full-year guidance?
View source ↗ - Newszacks.com·23d ago·Negative
SYK Stock Skids as Q3 Earnings and Sales Miss & 2026 Outlook Cut Stryker shares plunge 11.8% after Q3 earnings and sales miss estimates, prompting a 2026 outlook cut amid weak joint procedures and execution challenges.
View source ↗ - Newsprnewswire.com·23d ago·Positive
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS SAN FRANCISCO, Oct. 30, 2026 /PRNewswire/ -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists. The move lower wiped out over $10 billion of Stryker's market capitalization.
View source ↗ - News (RSS)zerohedge·23d ago·Neutral
…st estimate.Roblox (RBLX) slides 18% as the company reported a year-over-year decline in player engagement after deploying more robust child-safety measures.Stryker (SYK) falls 11% after slashing its outlook as the medical device company struggles to shake off the lingering effects of a cyberattack.Symbotic (SYM) inches 2% higher after robotics technology firm expanded an agreement with retail giant Walmart.Twilio (TWLO) is down 18% in the latest example of a software stock tumbling in the wake …
View source ↗ - Newszacks.com·23d ago·Neutral
SYK Q3 Earnings Call Highlights Softer Demand and Revised Outlook Stryker cuts its 2026 outlook amid weaker joint replacement demand and supply disruptions, despite MedSurg strength, margin gains and robotics investments.
View source ↗ - Newsmarketbeat.com·23d ago·Positive
What Stryker (SYK) Said on Its Q3 Earnings Call Stryker NYSE: SYK reported third-quarter organic sales growth of 7.7% and adjusted earnings per share of $3.52, while lowering its full-year outlook to reflect a slowdown in hip and knee procedures, lingering peripheral vascular supply constraints and execution risks tied to capital equipment sales.
View source ↗ - News247wallst.com·23d ago·Negative
Stryker's Guidance Cut Rattles Investors: What It Really Says About 2027 Medical device maker Stryker (NYSE:SYK | SYK Price Prediction) shares fell about 10% before the open Friday to $279.98, compared with Thursday's close of $311.75. The quarter missed expectations on both lines.
View source ↗ - News (RSS)seekingalpha·23d ago·Positive
Stryker Corporation (SYK) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·23d ago·Positive
Stryker Corporation (SYK) Q3 2026 Earnings Call Transcript Stryker Corporation (SYK) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·24d ago·Neutral
Stryker (SYK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·24d ago·Negative
Stryker (SYK) Q3 Earnings and Revenues Lag Estimates Stryker (SYK) came out with quarterly earnings of $3.52 per share, missing the Zacks Consensus Estimate of $3.56 per share. This compares to earnings of $3.19 per share a year ago.
View source ↗ - Newsbenzinga.com·24d ago·Positive
Stryker Q3 2026 Earnings Call Transcript Stryker (NYSE:SYK) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Stryker reports third quarter 2026 operating results Portage, Michigan, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2026:
View source ↗ - Newszacks.com·25d ago·Positive
SYK Q3 Earnings: Can Recovery Momentum Offset Operational Headwinds? SYK's Q3 earnings may reflect strong hospital equipment demand and cybersecurity recovery, but supply constraints, vascular disruptions and margin pressures remain.
View source ↗ - Newsseekingalpha.com·27d ago·Positive
It's Too Soon To Upgrade Stryker Corporation Stryker Corporation remains a global leader in medical technologies, with strong segment breadth and robust product innovation. SYK delivered solid financial growth in H1 2026, with revenue up 6.1% and EBITDA rising to $3.45 billion. Management projects 2026 organic revenue growth of 8.3–9.3% and adjusted EPS of $14.95–$15.10, supported by demographic tailwinds.
View source ↗ - Newszacks.com·27d ago·Neutral
Countdown to Stryker (SYK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS Get a deeper insight into the potential performance of Stryker (SYK) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Stryker completes acquisition of ZuriMED to enhance its shoulder offering Portage, Michigan, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced it has completed the acquisition of ZuriMED, a privately held company and developer of the FiberLocker® System.
View source ↗ - Newsdefenseworld.net·30d ago·Negative
Stryker Corporation $SYK Shares Purchased by CMH Wealth Management LLC CMH Wealth Management LLC raised its stake in shares of Stryker Corporation (NYSE: SYK) by 9.3% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,970 shares of the medical technology company's stock after acquiring an additional 1,699 shares during
View source ↗ - Newszacks.com·31d ago·Neutral
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newszacks.com·32d ago·Neutral
Stryker's Sonopet 3 Secures FDA Clearance to Improve Surgical Accuracy SYK's Sonopet 3 secures FDA clearance, promising enhanced surgical precision and efficiency, with a full commercial launch expected later this fall.
View source ↗ - Newszacks.com·34d ago·Neutral
Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal SYK's $400 million investment in CMR Surgical marks its entry into soft-tissue robotics, expanding its surgical portfolio with Versius technology.
View source ↗ - Newsglobenewswire.com·39d ago·Negative
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsprnewswire.com·39d ago·Neutral
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal Stryker has received FDA 510(k) clearance for Sonopet ® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, Sonopet 3 delivers enhanced power, precision and versatility.
View source ↗ - News (RSS)seekingalpha·40d ago·Neutral
Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story
View source ↗ - Newsseekingalpha.com·40d ago·Negative
Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story Stryker rebounded in 2Q26, with operating momentum restored after the prior quarter's cybersecurity disruption. 2Q26 sales rose 9.4% YoY to ~$6.6 billion; organic growth reached ~9%, demonstrating resilience despite earlier headwinds. Adjusted EPS increased ~18% to $3.69, and operating margin expanded 170 bps to 27.4%, reflecting improved profitability.
View source ↗ - News (RSS)financialpost·41d ago·Negative
Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery Portage, Mich., USA and Cambridge, England, Oct. 12, 2026 (GLOBE NEWSWIRE) — Strategic alliance combines CMR Surgical’s established platform and robotics expertise with Stryker’s scale, customer relationships and commercial reach to accelerate growth of the Versius Surgical Robotic portfolio Stryker will make an approximately $400 million (£300 million) preferred equity investment in CMR Surgical to […]
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Stryker announces leadership succession Portage, Michigan, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, today announced that as part of a planned succession process, Kevin Lobo will transition to the role of Executive Chair of the Board of Directors, effective January 1, 2027. Spencer Stiles, currently President and Chief Operating Officer of Stryker, will succeed Lobo as Chief Executive Officer and will also be appointed as a member of the compa…
View source ↗ - Newsseekingalpha.com·48d ago·Positive
Stryker: This Dividend Aristocrat Is Finally Cheap Again Stryker is upgraded to 'Strong Buy' after a significant price pullback to $275, offering compelling value relative to historical valuation. SYK demonstrates robust organic sales growth, balanced across geographies and segments, with strong demand and elevated equipment backlogs. Key growth drivers include Mako robotic-assisted procedures, ASC expansion, and Smart Care platform integration, supporting double-digit EPS growth expectations.
View source ↗ - Newsprnewswire.com·52d ago·Positive
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS SAN FRANCISCO, Oct. 1, 2026 /PRNewswire/ -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists. The move lower wiped out over $10 billion of Stryker's market capitalization.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Stryker to announce third quarter 2026 financial results Portage, Michigan, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, October 29, 2026, to discuss its third quarter 2026 financial results.
View source ↗ - Newszacks.com·60d ago·Positive
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now? ISRG's rapid procedure growth, expanding robotics ecosystem and recurring revenues highlight its growth path amid MedTech shifts.
View source ↗ - Newszacks.com·60d ago·Neutral
Can Stryker Vehicle Demand Support General Dynamics' Growth? GD's Stryker contract modification lifts cumulative value to $278.9M, supporting Land Systems demand through December 2028.
View source ↗ - Newszacks.com·60d ago·Positive
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
View source ↗ - Newsglobenewswire.com·60d ago·Positive
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS SAN FRANCISCO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists.
View source ↗ - Newszacks.com·66d ago·Neutral
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX SYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.
View source ↗ - Newsglobenewswire.com·67d ago·Positive
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists.
View source ↗ - Newsprnewswire.com·67d ago·Neutral
Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™ New additions advance surgical planning, implant flexibility and connected care across Stryker's Foot & Ankle portfolio Stryker is launching Prophecy® Surgical Planning for the Incompass™ Total Ankle System and introducing Hoffmann®LRF smartHEX™ at the 2026 American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle. Prophecy® Surgical Planning, which has su…
View source ↗ - News (RSS)seekingalpha·69d ago·Neutral
Stryker: Operational Issues Have Created An Opportunity
View source ↗ - Newsseekingalpha.com·69d ago·Negative
Stryker: Operational Issues Have Created An Opportunity Stryker's share price has declined significantly in recent months on the back of operational issues, valuation concerns, and weaker orthopedic procedure volume growth. Despite headwinds, Stryker's growth is still solid and should rebound once the Vascular manufacturing issue is resolved. Further margin expansion is also an underappreciated part of the Stryker story.
View source ↗ - Newsbusinesswire.com·74d ago·Negative
Securities Fraud Investigation Into Stryker Corporation (SYK) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON STRYKER CORPORATION (SYK), CLICK HERE TO INQUIRE ABOUT PO…
View source ↗ - News (RSS)seekingalpha·75d ago·Positive
Stryker Corporation (SYK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·75d ago·Neutral
Stryker drops after comments on vascular and ortho segments
View source ↗ - Newsseekingalpha.com·75d ago·Positive
Stryker Corporation (SYK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Stryker Corporation (SYK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - News (RSS)investing·75d ago·Neutral
Stryker Corporation stock hits 52-week low at 280.99 USD
View source ↗ - News (RSS)yahoo·79d ago·Positive
Stryker (SYK) is Buying ZuriMED. Can FiberLocker Strengthen its Shoulder Portfolio?
View source ↗ - Newsglobenewswire.com·79d ago·Neutral
Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference Portage, Michigan, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor, as previously reported.
View source ↗ - News247wallst.com·79d ago·Positive
Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.
View source ↗ - Newszacks.com·80d ago·Negative
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.
View source ↗ - News (RSS)investing·82d ago·Neutral
Stryker completes first surgery using Apple Vision Pro app
View source ↗ - Newszacks.com·82d ago·Neutral
Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio SYK's planned ZuriMED acquisition adds the FiberLocker System, aiming to strengthen its shoulder portfolio and rotator cuff care capabilities.
View source ↗ - Newsprnewswire.com·82d ago·Neutral
Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information Stryker announced the successful completion of the first surgical procedure, a hip arthroscopy, using SportSuite Vision on Apple Vision Pro at a leading academic medical center. Stryker received FDA De No…
View source ↗ - News (Marketaux)gurufocus.com·82d ago·Positive
SYK Looks 22.2% Undervalued on GF Value™ On August 31, 2026, Stryker Cor[+292 characters]
View source ↗ - Newsglobenewswire.com·83d ago·Neutral
Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced it has signed a definitive agreement to acquire ZuriMED, a privately held company and developer of the FiberLocker® System. This commercialized technology provides a novel approach for rotator cuff augmentation with increased biomechanical strength to address a key clinical failure mode…
View source ↗ - News (RSS)businessinsider·87d ago·Neutral
Stryker to participate in the 2026 Wells Fargo Healthcare Conference <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />Portage, Michigan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on <b>Tuesday, September 8, 2026</b>, at the Encore Boston Harbor.Preston Wells, Vice President, Chief Financial...
View source ↗ - Newsglobenewswire.com·87d ago·Neutral
Stryker to participate in the 2026 Wells Fargo Healthcare Conference Portage, Michigan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor.
View source ↗ - Newszacks.com·88d ago·Neutral
Do Options Traders Know Something About Stryker Stock We Don't? Investors need to pay close attention to SYK stock based on the movements in the options market lately.
View source ↗ - Newszacks.com·93d ago·Positive
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
View source ↗ - Newsseekingalpha.com·94d ago·Neutral
Stryker: The Sell-Off Creates A Better Entry Point, But Q2 Wasn't Perfect Stryker (SYK) rebounded in Q2 with 9% organic growth, restoring confidence after a weak Q1. Both MedSurg & Neurotech and Orthopaedics segments sharply accelerated, indicating Q1 weakness was temporary. Guidance was modestly adjusted, but demand remains strong and growth is broad-based across product lines.
View source ↗ - News (RSS)investing·95d ago·Neutral
Thomas Kean Jr. trades in Alphabet, Amazon, and Stryker stocks
View source ↗ - News (RSS)seekingalpha·96d ago·Neutral
Stryker Corporation: Hold For Quality, Wait For The Dip
View source ↗ - News (Marketaux)seekingalpha.com·96d ago·Neutral
Stryker Corporation: Hold For Quality, Wait For The Dip (NYSE:SYK) Stryker Corporation: Hold For Quality, Wait For The Dip (NYSE:SYK)
View source ↗ - Newszacks.com·100d ago·Positive
SYK Stock Gains 3.8% Since March-End: What's Driving the Uptrend? Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.
View source ↗ - Newszacks.com·101d ago·Positive
Is SYK Worth Buying as Growth Improves but Execution Risks Persist? Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.
View source ↗ - Newszacks.com·101d ago·Neutral
Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half? Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.
View source ↗ - Newszacks.com·101d ago·Positive
Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next? Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $5.03 per share
Typical surprise +1.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$3.52 vs $3.55miss
- Thu, Jul 30$3.69 vs $3.49beat
- Thu, Apr 30$2.60 vs $2.98miss
- Thu, Jan 29$4.47 vs $4.40beat
- Thu, Oct 30$3.19 vs $3.13beat
- Thu, Jul 31$3.13 vs $3.07beat
Estimates and results for SYK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SYK officers and directors.
- Bought
- $27k
- Sold
- $397.8m
5 trades
42 trades
- Stryker Ronda Esold
- Stryker Ronda Esold
- Stryker Ronda Esold
- Stryker Ronda Esold
- Stryker Ronda Esold
- Stryker Ronda Esold
- Crotty Dylan Bramsold
- Stryker Ronda Esold
53 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Thomas Keanhouse · NJ07 · disclosed Nov 19, 2026 (23d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (27d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Sell$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Oct 30, 2026 (30d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (28d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (14d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Aug 19, 2026 (28d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Sell$15,001 - $50,000
- Thomas Keanhouse · NJ07 · disclosed Jul 16, 2026 (44d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$15,001 - $50,000
- Thomas Keanhouse · NJ07 · disclosed Feb 20, 2026 (28d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$15,001 - $50,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (89d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (447d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 12, 2026 (33d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Dec 19, 2025 (29d later)Sell$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2025 (27d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 18, 2025 (32d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (38d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
